Aequus Pharmaceuticals says it will maintain commercial relationship with Sandoz into 2022

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) will maintain its current commercial relationship pertaining to the Vistitan glaucoma drug, with Sandoz into 2022.  

As a specialty pharmaceutical company, Aequus Pharmaceuticals is focused on developing, advancing and promoting differentiated products. The product line includes several medications for eye health as well as an anti-rejection drug (Tacrolimus IR) for transplant recipients. 

There is potential to extend the current partnership beyond February 2022 and could expand to include additional products beyond Vistitan and Tacrolimus IR. 

READ: Aequus Pharmaceuticals first quarter results show good progress in spite of the coronavirus pandemic

As pandemic-related lockdowns ease, the sales team at Aequus has increased outside sales and travel activity across Canada. The company plans to expand these efforts throughout the second half of the year, while continuing to engage customers digitally.

“We are delighted with the team’s flexibility to embrace digital technologies and support our customers and their patients throughout the pandemic. We anticipate many of these capabilities will continue to be leveraged to drive efficiencies once the pandemic is over,” Doug Janzen, Chairman and CEO of Aequus noted in the statement. “We will have a strong digital presence at key conferences in eye care and recently launched a new website for Vistitan.”

Contact Georgia at [email protected]

Follow her on Twitter @MissInformd

Story by ProactiveInvestors